recall radarNODEJAVASCRIPT.COM

Biologic or vaccine recall notices

257notices on file
4publishing bodies
4recorded as Class 1

Notices

Most recently updated first, out of 257 notices in this category.

IMAAVY: Affected lots may contain glass particles
Drugs and health products · 2026-09-21 · Class 2
TZIELD (teplizumab) and the Risk of Viral Reactivation
Marketed health products · 2026-09-14 · Class not stated
Two lots of Omnitrope injectable human growth hormone recalled due to cracked cartridges
Communications and Public Affairs Branch · 2026-07-08 · Class 1
Ozempic Solution: Cracked glass cartridges
Drugs and health products · 2025-10-31 · Class 2
YF-Vax powder for solution; Cracked vials
Drugs and health products · 2025-08-07 · Class 2
Gamunex solution; may cause allergic / hypersensitivity type reaction
Drugs and health products · 2025-06-19 · Class 3
Kimmtrak Solution; Out of specification (in-vitro potency assay)
Drugs and health products · 2025-06-16 · Class 2
Neupogen vials; Out of specification (Stability)
Drugs and health products · 2025-03-27 · Class 3
Panhematin powder for solution: Sterility concern
Drugs and health products · 2024-09-13 · Class 1
Tisseel Kit; Out-of-specification (Dissolution)
Drugs and health products · 2024-05-23 · Class 2
Cord blood banked at the Canadian Cord Blood bioRepository in Edmonton, Alberta, may pose
Communications and Public Affairs Branch · 2023-11-01 · Class not stated
BOOSTRIX: Syringes may be cracked in affected lot.
Drugs and health products · 2022-10-07 · Class 2
ZOLGENSMA (onasemnogene abeparvovec) and Fatal Cases of Acute Liver Failure
Marketed health products · 2022-09-12 · Class not stated
IMVAMUNE Vaccine: Updated Storage Conditions and Shelf Life
Marketed health products · 2022-07-29 · Class not stated
Health Canada is updating the labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 v
Communications and Public Affairs Branch · 2021-11-09 · Class not stated
Authorization of Sotrovimab for Injection for Use in Relation to the COVID-19 Pandemic
Marketed health products · 2021-10-04 · Class not stated
One lot of the hypoglycemia treatment Glucagon recalled as it may pose serious health risk
Communications and Public Affairs Branch · 2021-09-25 · Class not stated
Health Canada updates Pfizer-BioNTech COVID-19 vaccine label to reflect very rare reports
Communications and Public Affairs Branch · 2021-08-06 · Class not stated
Health Canada updates Pfizer-BioNTech and Moderna COVID-19 vaccine labels to include infor
Communications and Public Affairs Branch · 2021-06-30 · Class not stated
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome
Marketed health products · 2021-06-29 · Class not stated
Health Canada issues label change on the AstraZeneca and COVISHIELD COVID-19 vaccines
Communications and Public Affairs Branch · 2021-06-29 · Class not stated
Janssen COVID-19 Vaccine and the Risk of Thrombosis with Thrombocytopenia
Marketed health products · 2021-04-26 · Class not stated
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Thrombosis with Thrombocytopenia
Marketed health products · 2021-03-24 · Class not stated
Pfizer-BioNTech COVID-19 Vaccine: Updated Storage and Transportation Conditions
Marketed health products · 2021-03-08 · Class not stated
Authorization of Janssen COVID-19 Vaccine with English-only Vial and Carton Labels
Marketed health products · 2021-03-08 · Class not stated
Authorization of COVISHIELD with English-only Vial and Carton Labels
Marketed health products · 2021-03-01 · Class not stated
Authorization of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels
Marketed health products · 2021-03-01 · Class not stated
Authorization of Moderna COVID-19 Vaccine with English-only Vial and Carton Labels
Marketed health products · 2020-12-23 · Class not stated
Pfizer-BioNTech COVID-19 vaccine: Health Canada recommendations for people with serious al
Communications and Public Affairs Branch · 2020-12-12 · Class not stated
Clinical trial looking at the potential use of convalescent plasma to treat COVID-19
Communications and Public Affairs Branch · 2020-05-01 · Class not stated
Health Canada clarifies position on Platelet Rich Plasma treatments
Communications and Public Affairs Branch · 2019-07-26 · Class not stated
DARZALEX (daratumumab) and Hepatitis B Virus Reactivation
Marketed health products · 2019-03-25 · Class not stated
TECENTRIQ® (atezolizumab) - Risk of Immune-Related Myositis
Marketed health products · 2019-03-13 · Class not stated
TECENTRIQ® (atezolizumab) - Risk of Immune-Related Nephritis
Marketed health products · 2018-09-18 · Class not stated
Several GlaxoSmithKline Inc. vaccines: Potential Risk of Underdosing
Marketed health products · 2018-05-01 · Class not stated
ZINBRYTA (daclizumab beta) - Voluntary Withdrawal in Canada due to Risk of Encephalitis
Marketed health products · 2018-03-16 · Class not stated
Shortage of Erwinase for Injection and Replacement with UK Labelled Stock
Marketed health products · 2018-02-27 · Class not stated
TECENTRIQ (atezolizumab) - Risk of Myocarditis
Marketed health products · 2018-02-14 · Class not stated
Cord blood banked at the Cord Blood Bank of Canada can be used only by the donor
Communications and Public Affairs Branch · 2017-10-17 · Class not stated
Erwinase for Injection - Shortage
Marketed health products · 2017-07-12 · Class not stated
Pg 8528/Pg 8527/Pg 8535/ Pg 8536 Washer-Disinfectors
Medical devices · 2017-05-31 · Class 3
Erwinase for Injection - Shortage and Replacement with UK Labelled Stock
Marketed health products · 2017-05-03 · Class not stated
Erwinase for Injection - Replacement with UK Labelled Stock
Marketed health products · 2017-04-12 · Class not stated
Erwinase for Injection - Special Handling Instructions
Marketed health products · 2017-02-07 · Class not stated
Erwinase for Injection - Shortage and Special Handling Instructions
Marketed health products · 2017-01-09 · Class not stated
Direct-acting antivirals, used for hepatitis C, may reactivate hepatitis B
Communications and Public Affairs Branch · 2016-12-01 · Class not stated
Erwinase for Injection - Shortage and Replacement with UK Labelled Stock
Marketed health products · 2016-09-16 · Class not stated
Information Update - Gardasil vaccine safety studies show no new risks
Communications and Public Affairs Branch · 2015-12-09 · Class not stated
STELARA (ustekinumab) - Risk of Rare Serious Skin Conditions - For Health Professionals
Marketed health products · 2014-11-21 · Class not stated
STELARA (ustekinumab) - Risk of Rare Serious Skin Conditions - For the Public
Marketed health products · 2014-11-21 · Class not stated
Safety information on the risk of blood clots with immunoglobulin products
Communications and Public Affairs Branch · 2014-10-09 · Class not stated
System 1 Base 100/120v (2013-02-20)
Medical devices · 2014-03-18 · Class 2
Avastin (bevacizumab) - Cases of Necrotizing Fasciitis Reported - For the Public
Marketed health products · 2013-05-02 · Class not stated
Voluntary Suspension of Flu Vaccines (Agriflu and Fluad) Lifted
Communications and Public Affairs Branch · 2012-10-31 · Class not stated
Novartis Suspends Distribution of Seasonal Flu Vaccines Agriflu and Fluad in Canada as a P
Communications and Public Affairs Branch · 2012-10-26 · Class not stated
Sanofi Pasteur recalls tuberculosis (BCG) vaccine
Communications and Public Affairs Branch · 2012-06-30 · Class not stated
XIGRIS [drotrecogin alfa (activated)] - Worldwide Withdrawal - Notice to Hospitals
Marketed health products · 2011-10-28 · Class not stated
XIGRIS [drotrecogin alfa (activated)] - Worldwide Withdrawal - For Health Professionals
Marketed health products · 2011-10-28 · Class not stated
XIGRIS [drotrecogin alfa (activated)] – Worldwide Withdrawal – For the Public
Marketed health products · 2011-10-28 · Class not stated
Xigris (drotrecogin alfa) withdrawn worldwide
Communications and Public Affairs Branch · 2011-10-25 · Class not stated
Trasylol (aprotinin) - Important New Safety Information - Notice to Hospitals
Marketed health products · 2011-09-21 · Class not stated
Trasylol (aprotinin) – Important New Safety Information – For the Public
Marketed health products · 2011-09-21 · Class not stated
Potential dangers of using donor semen from questionable sources
Communications and Public Affairs Branch · 2011-08-29 · Class not stated
Important information regarding semen donation
Communications and Public Affairs Branch · 2010-12-07 · Class not stated
ACTEMRA (tocilizumab) - Risk of Fatal Anaphylaxis - For Health Professionals
Marketed health products · 2010-09-17 · Class not stated
ACTEMRA (tocilizumab) - Risk of Fatal Anaphylaxis - For the Public
Marketed health products · 2010-09-17 · Class not stated
AVASTIN (bevacizumab) - Association with Allergic Reactions - For Health Professionals
Marketed health products · 2010-08-23 · Class not stated
AVASTIN (bevacizumab) - Association with Allergic Reactions - For the Public
Marketed health products · 2010-08-23 · Class not stated
Rotarix - Presence of Porcine Circovirus Type 1 (PCV-1) - For Health Professionals
Marketed health products · 2010-07-30 · Class not stated
RotaTeq - Presence of Porcine Circovirus (PCV) DNA
Marketed health products · 2010-07-30 · Class not stated
Important Information Regarding Rotavirus Vaccines: Rotarix and RotaTeq
Communications and Public Affairs Branch · 2010-05-07 · Class not stated
New Expiry Date for Unused Adjuvanted H1N1 Vaccine (Arepanrix)
Communications and Public Affairs Branch · 2010-04-09 · Class not stated
Archived - Market withdrawal of Raptiva (efalizumab) in Canada- For the Public
Marketed health products · 2009-06-17 · Class not stated
Archived - Synagis (palivizumab) - Abbott Laboratories Limited
Marketed health products · 2009-02-23 · Class not stated
Archived - Suspension of marketing of Raptiva (efalizumab) in Canada - For the Public
Marketed health products · 2009-02-20 · Class not stated
Important Safety Information on HEPARIN - Notice to Hospitals
Marketed health products · 2008-03-28 · Class not stated
Archived - Review Determines Measles, Mumps and Rubella Vaccine Lots Can be Released for U
Communications and Public Affairs Branch · 2008-03-03 · Class not stated
Archived – Three Lots of Measles, Mumps and Rubella Vaccine Suspended from Use
Communications and Public Affairs Branch · 2007-12-11 · Class not stated
Important Safety Information on RITUXAN (rituximab) - For Health Professionals
Marketed health products · 2007-08-13 · Class not stated
For Health Professionals - Information Regarding Myozyme (alglucosidase alfa)
Marketed health products · 2007-05-17 · Class not stated
Archived - AVASTIN® (bevacizumab) - Advisories, Warnings and Recalls for the Public
Marketed health products · 2006-10-27 · Class not stated
Archived - Important Safety Information on Trasylol - Bayer Inc.
Marketed health products · 2006-02-28 · Class not stated
Archived – Important New Safety Information Regarding ZENAPAX (Daclizumab)
Marketed health products · 2003-11-11 · Class not stated
Archived – Use of Kineret®(anakinra) in Combination with Etanercept
Marketed health products · 2002-12-17 · Class not stated
Archived – Important Safety Information regarding Refludan® – Berlex Canada Inc.
Marketed health products · 2002-10-30 · Class not stated
Archived – Thrombotic Events and Immune Globulin Intravenous (IGIV) – Baxter
Marketed health products · 2002-04-12 · Class not stated
Archived - Important Safety Information - EPREX (epoetin alfa) - Janssen-Ortho Inc.
Marketed health products · 2001-11-26 · Class not stated
Archived - Important Drug Warning On Remicade™
Marketed health products · 2001-10-23 · Class not stated
Archived - Important Drug Warning - RITUXAN - Hoffmann-La Roche Ltd.
Marketed health products · 2001-05-16 · Class not stated
Archived - Important Drug Warning from the Manufacturer Vitex Inc. on PLAS+®SD
Marketed health products · 2000-10-20 · Class not stated
Archived - Letter to Hospitals Regarding Abbokinase
Marketed health products · 1999-07-23 · Class not stated
Archived - Update Letter to Hospitals Re ABBOKINASE (Urokinase)
Marketed health products · 1999-03-24 · Class not stated
Archived - Letter to Hospitals Re: Abbokinase
Marketed health products · 1999-02-04 · Class not stated
Archived - Notice to Hospitals from the Bureau of Drug Surveillance
Marketed health products · 1998-11-27 · Class not stated
Archived - Notice to hospitals from the Bureau of Drug Surveillance
Marketed health products · 1998-08-07 · Class not stated

Biologic or vaccine by class

Counted from the class recorded on each notice. Blank classes are included.

Biologic or vaccine — notices by classCounted from the class recorded on each notice.0100200300400500Class 1: 4Class 1Class 2: 8Class 2Class 3: 4Class 3Class not stated: 241Class not statSource: Government of Canada Recalls and Safety Alerts open data.

Scroll the chart sideways to see all of it.

Source: Health Canada — Recalls and safety alerts (open data).

Privacy

This site publishes records that governments already publish. It sets no cookie and makes no request to Google unless you accept one. Read more below.

About this record

Every recall notice published by Health Canada: the product, the issue recorded against it, the class assigned, and the official notice itself. A record of what was published, on the date it was published.

Source: Health Canada — Recalls and safety alerts (open data) — Open Government Licence – Canada. Data refreshes daily. Every page links the row it came from.

What this site is not. It is a copy of an official record. It is not a judgement about any business, building or person, and it is not advice. If the record is wrong, the source above is where it is corrected.